H C Wainwright new target share price ... 26 Jul 2021.... $5.00 C
w
Prepare yourselves for this message board to light with newbies. Some will be smart and informative posters. Some will not.
D
PharmaTher Holdings Ltd. OTCQB: PHRRF Rating: BUY 12-Month Target Price: $1.50 Tuesday closing price: $0.68 Ketamine-focused PharmaTher is “targeting the psychedelic space from multiple angles, resulting in a de-risked pipeline,” Maxim analysts say. The company is developing a pipeline of ketamine-based therapeutics to treat mental health and neurodegenerative disorders. It is looking at Ketamine as a dual solution for Parkinson’s patients, as the depressive drug can both alleviate involuntary movements and depression, which prevails in over 50% of Parkinson's patients. A phase 2 trial on this research is on its way.
c
Hey. We talk in this place. Just keep quiet and make cool money with this stock.
c
Don't miss buying under $1
k
what's with the jump at the end of the day 🤔
A
Investor presentation update tomorrow 😃😃
k
there she goes
k
what's driving this up today
A
Incredible news. This will by far be the 1st mainstream psychedelic FDA approved. Revolutionary.
D
Nice volume, keep holding this is just the beginning 😀
OTCQB: PHRRF
Rating: BUY
12-Month Target Price: $1.50
Tuesday closing price: $0.68
Ketamine-focused PharmaTher is “targeting the psychedelic space from multiple angles, resulting in a de-risked pipeline,” Maxim analysts say.
The company is developing a pipeline of ketamine-based therapeutics to treat mental health and neurodegenerative disorders. It is looking at Ketamine as a dual solution for Parkinson’s patients, as the depressive drug can both alleviate involuntary movements and depression, which prevails in over 50% of Parkinson's patients. A phase 2 trial on this research is on its way.